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Autoproteolytic activation and processing of human polymorphonnclear leucocyte (PMNL) type IV pracollagenase (gelatinase) was initiated by 
HgC& and was investigated by kinetic analysis and N-terminal sequence determination orthe reaction products. In the first instance the propeptide 
domain was lost by subsequent cleavage of the Asp”-Lcu , I6 Glu”‘-MctJ’, Lcul’-Led3 and Ala7J-Met’5 peptide bonds, The PRCGVPD sequence 
motif (residues Pro”-Asp?, which is conserved in all metalloproteinases andexpected to be relevant for latency, remained uncleaved at the activated 
enzyme, The generated intermediate was further processed by three C-terminal cleavages. The Gl~~~“-Leu~‘, AlaW6-GIu507 and Ala’9n-Leu’g’ bonds 
were hydrolysed sucessively. From the fragmentation products we were able to conclude that three released fragment peptid es contained unpaired 
free cystcine with the residues CysJ9’, CysbJ3, Cys a3, Cleavage of lhc first C-terminal peptide bond resulled in the loss ofonc of the conserved Cys 
residues of the hemopexin.like domain, whereas the Cys residue of the PRCGVPD motif was retained at the fully active enzyme. The possibility 
of an entirely different activation mechanism for PMNL type IV procollagenase is discussed. 
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1. INTRODUCTION 
Type IV collagenases (gelatinases) play key roles in 
matrix remodeliing and basement membrane degrada- 
tion and contribute to the metastatic potential of tumor 
cells [l]. The two type IV collagenases are unique 
members of the matrix metalloprotcinase family with 
regard to their domain structure. The M, 72,000 and the 
M, 98,000 type IV collagenase share a fibronectin-like 
domain, which is inserted 175 residues preceeding the 
proposed zinc binding motif. This domain is homolo- 
gous to the collagen binding motif of fibronectin and 
responsible for gelatin binding of the proenzymes [2]. 
The A4, 98,000 type IV collagenase contains an addi- 
tional domain with sequence similarities to the CL? chain 
of type V collagen [33. The function of this insertion 
behind the zinc binding motif has still to be determined. 
As sequence data became available different groups 
developed theoretical activation mechanisms to explain 
theexperimental data [lO,ll]. A stable complex between 
\ the conserved Cys residue of the DRCGVPD sequence 
motif within the propeptide domain and the active site 
zinc might be the basis for latency. It is believed that all 
modes of activation require the removal of this Cys 
residue out of the coordination sphere of the zinc bind- 
ing centre as the most important step. This has recently 
been supported by site directed mutagenesis experi- 
ments with transin, the rat homologues of human stro- 
melysin [ 12,131. Mercurial compounds as well as oxygen 
radicals are assumed to activate by modifying the 
chelating cysteine sulfhydryl group. Latent metal- 
loprotcinases are activated by human neutrophils by an 
oxidative process in vivo [14]. 
The rnode of activation of metalloproteinases in vivo 
is unknown. Activation in vitro was the target of inten- 
sive studies during the last ten years [3-g]. Exposure of 
the purified proenzymes to proteinases, organomer- 
curials, oxygen radicals or chaotropic agents led to the 
generation of enzymatic activity. 
In this paper we present he first data for the indi- 
vidual steps in the activation process of PMNL type IV 
procollagenase induced by HgC12 and discuss a 
modified activation mechanism for this enzyme. 
2. MATERIALS AND METHODS 
/ibbreviutfons: PMNL, polymorphonudear leucocytcs; RP-HPLC, 
reversed-phase high-performance liquid chromatography; TBST, 
Tris-buffered saline Tween; TIMP-I, tissue inhibitor of mctal- 
Ioproteinases-1 . 
Dinitrophenyl-peptide was purchased from Bachcm (Bubendorf, 
Switzerland), All other chemicals were purchased from Merck 
(Darmstadt, Germany). 
Correspdewe ad~fresx H. Tscheschc, Universittit Uielefeld, Fakulttit PMNL type IV procollagenase was puritied as recently published 
flir Chcmie, Abteilung Biochemie, Postfach 8640, W-4800 Biclefcld I, [I 51. Proenzyme activation was achieved by incubation whh MgCI, at 
Germany. Fax: (49) (521) 106 6146. 37°C Type IV collagenase uclivity was determined by proteolytic 
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degradation of the synlhetic octapeptidc (dinitrophcnyl-Pro-Gin-lie- 
Ala.Gly-Gln.D-Ar&OH) as described by Masui [IB]. 
2.3. Protein deterrninaiioa 
Protein concentrations were estimated from Azao assuming an 
absorption coefficient of 1.0 M-‘-cm-‘. 
2.4. Kinetic analysis of HgC&induced uctivatiorr of PMNL type IV 
procollagenase and separatiorr o$ rltc rraction products by AP- 
HPLC 
PMNL type IV procollagenase was activated for between 5 min to 
2 h at 37°C using 1 mM HgC12. The reaction mixture was directly 
subjected to a Bakerbond wide port &-column (4.9 x 250 mm). The 
separations ofthe reaction products wcrc performed at a constant Row 
rate of 0.8 ml/rnin using a linear gradient from O-60% acetonitrilc. 
Peptidcs and proteins were detected at 214 nm, collected, lyophilised 
and subjected to automated amino acid sequence determintation using 
a microsequencer (Model 810, Knauer, Berlin, Germany). 
2.5. SDS/PAGE 
SDS/PAGE was performed according to the method of Lacmmli 
[17]. The proteins were visualised by silver staining [IS]. 
3. RESULTS 
3.1. Autoproteoiytic activution and processirtg of Amun 
type IV procollugenuse hduced by &Cl2 
Type IV procollagenase was purified from human 
PMN leucocytes. The N-terminus of the enzyme was 
found to be identical to that of the proenzyme from 
SV40-transformed lung fibroblasts [3,15]. As shown by 
SDS/PAGE (Fig. 1, lane 2), PMNL type IV procol- 
lagenase consists of three forms with different molecu- 





Fig. 1. Time-dependent activation of PMNL type IV procollagenase 
by HgCl$ SDS/PAGE analysis ofgenerated products. (Lane I) molec- 
ular mass marker; (lane 2) starting material, PMNL type IV procol- 
lagcnass; (lanes 3-7) after exposure to I mM HgC12 for 5. 15, 30.60 
and I20 min, respectively. a, latent M, 98,000 form; a’. first active form 
of a, A4, 88,000; b, latent 1w, 125,000 form; b’, first active form of b, 
M, 115,000; c, latent M, 220.000 form; c’, first active iorm of c, iri, 
200,000. The band pattern of lane 7 remains unchanged over H period 
of about 12 h, then further autolysis becomes visible by additional 
bands. 
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Fig. 2. Time-dependent activity of PMNL type IV collagcnase during 
lar masses (kf, 220,000, 125,000 and 98,000). Under 
reducing conditions these forms result in A4’, 98,CKKJ and 
M, 28,000 subunits [15]. The isolated latent enzyme 
showed no activity against the synthetic DNP-octa- 
peptide. 
Time-dependent activation with HgC12 was inves- 
tigated by SDS/PAGE and by determination of type IV 
collagenase activity as measured by proteolytic degra- 
dation of the synthetic DNP-octapeptide. 
The SDS/PAGE showed that the three type IV col- 
lagenase proenzyme forms were completely trans- 
formed after 2 h into products with lower molecular 
masses. Determination of the activity (Fig. 2) showed 
that activation was complete after 2 h. The activity 
correlates with the formation of the products with lower 
molecular masses hown by SDS/PAGE. Reduction in 
molecular mass is therefore necessary for generation of 
activity. After overnight incubation with HgCl:! at 37OC 
the activity decreased ue to autolysis of the enzyme. 
Since SDS/PAGE analysis of the activation was not 
very instructive, autoproteolytic processing of human 
PMNL type IV procollagenase (Iw, 220,000, M, 
125,000, M, 98,000), induced by HgQ, was analysed by 
RP-HPLC. This allowed separation and isolation of the 
reaction products which could be subjected to N-ter- 
minal sequence determination. Autoproteolytic 
cleavage of the enzyme and further cleavage of the liber- 
ated reaction products resulted in a timedependent 
generation of various peptides. 
After 5 min of HgCl,-incubation four peptides could 
be isolated (Fig. 3, peptides I-IV). The ‘N-terminal se- 
quences of these peptides revealed that the three peptide 
bonds AspIS-Leu’“, Glum-Met” and Lcu5’Leus3 were 
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Fig. 3. Time-dependent processing of PMNL type IV procollagenase induced by HgC12. (A) propepdde; (B) catalytic domain; (C) fibranectin-like 
domail inserted into the catalytic domain B; (D) type V collagen-like domain; (E) hemopexin-like domain; (I-W) propeptide fragments in the order 
of their appearance; (Y-VII) C-terminal fragments in the order of their appearance; (I-13) chronological order of formation of the reaction 
products. 
cleaved. Sequence determinations of the enzyme iso- 
lated by RP-HPLC after 10 min activation with HgCI, 
revealed the live N-terminal residues .41a’, Leu’“, Met”, 
Leu$’ and Met’j. From this we concluded that the four 
peptides were sucessivly formed, without the loss of the 
PRCGVPD region, corresponding to a four-step pro- 
peptide truncation. 
During the next 10 rnin of H&l? incubation two 
further peptides were isolated (Fig. 3, peptides V and 
VI). Their formation resulted from the hydrolysis of the 
Gl~~~~--Leu~~’ and the AlaS06-G1u507 peptide bond. The 
Met75-Glu6W enzyme corresponded to the M, 88,000 
and the Met”-Alaso enzyme to the M, 73,000 (Fig. 1, 
lane 7) active type IV collagenase forms. 
The next molecular mass reduction of type IV col- 
lagenase was observed in the form of the isolation of 
another peptide after 60 min incubation with H&I, 
(Fig. 3, peptide VII). This peptide was created from 
cleavage of the Ala3”‘-Leu3’g peptide bond, which re- 
sulted in the formation of the M, 63,000 active type IV 
collagenase form. This could not be visualized by SDS/ 
PAGE (Fig. 1). The isolation of these three peptides 
(V-VII) corresponded to a three-step C-terminal 
truncation of the enzyme. 
For the kf, 125,000 proenzyme form the SDS/PAGE 
showed a loss of 10,000 Da, which corresponded to the 
formation of the ,Ur 88,000 enzyme form. 
The dimer of the M, 98,000 unit, which shows a mo- 
lecular mass of 220,000 on SDS/PAGE, was succes- 
sively cleaved into h#, 200,000 and 150,000 activation 
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products. The former corresponded to the Mr 88,000 
monomer and the later to the Mr 73,000 monomer. 
The seven primary split products of the autoproteoly- 
tic process underwent further cleavages. During the first 
15 min of HgCI:! incubation four secondary split 
products were isolated, which resulted from the sixth 
primary peptide (Fig. 3, peptide VI) via hydrolysis of 
the LeuGo6-PheGo7 followed by hydrolysis of the Leus3C 
Iles3’ peptide bond (Fig. 3, cleavages 7 and 8). After 60 
min activation with HgCIz two new propeptide frag- 
ments could be isolated. The fourth primary split prod- 
uct was cleaved at the ThP4-Gly6’ peptide bond (Fig. 
3, cleavage 9). After the next 60 min incubation six 
further peptides occurred. They correspond to three 
cleavages of three C-terminal split products (Fig. 3, 
cleavages 11-13). The Pro’“G-Th~7g peptide bond of the 
seventh primary peptide was hydrolysed. The peptide 
IleS3’-LeuW6 was cleaved at the Lys557-Leu5’8 and the 
peptide Phe607-G1uG6” at the Ala6”-GlnG2” peptide 
bond. 
In summary, 19 peptides were isolated during 2 h of 
H&I? incubation. The main products of these peptides 
are the four propeptide split products (Fig. 3, I-IV) and 
the two C-terminal peptides (Fig. 3, V and VI), which 
are formed during the first 10 min. 
The hemopexin-like domain of type IV collagenase 
contains three cysteine residues. The two cysteines, 















Fig. 4. Demonstration of the different retention times of the cysreinc- 
carrying peptides RP-HPLC elution profile aher 2 h exposure to 1 mM 
HgCll (I 50 ,ug type IV collagcnase). (1) peptide Th?79-AlaS0b contains 
Cy@‘; (2) peptide Leuw7-Asp6”6 contains Cysbn3: (3) peptidc GluSO’- 
GIueti contains Cys”‘. 
cyd9 and Cys’*‘, which correspond to the two con- 
served cysteines in the hemopexin-like domains of all 
metalloproteinases, are thought to be disulfide bridged 
[21]. CysGss i  an additional cysteine of the C-terminal 
domain of the type IV collagenase. The two peptides: 
GluSo7-Glu6GG (contains CysGss; Fig. 4, peak 2) and 
Leufi6’-AspGBG (contains CY$‘~~; Fig. 4, peak 3) are main 
products of the autoproteolytic processing. The peptide 
Leu3Jg-AlaSo6 (contains Cyso9’; Fig. 4, peak 1) was not 
isolated until after 60 min incubation with HgCl,. But, 
all three peptides eluted under non-reducing conditions 
at different retention times under RP-HPLC conditions 
(Fig. 4, peaks 1 ,2,3; 30.8, 34.5, 44.5% acetonitrile) 
4. DISCUSSlON 
Mercurial compounds possess no proteolytic activity, 
but they catalyse the autoproteolysis of metal- 
ioproteinases. Our results show that the activation 
mechanism of PMNL type IV procollagenase in vitro 
is very complex. A four-step truncation from the N- 
terminal end is followed by a three-step loss of C-ter- 
minal fragments. The PRCGVPD sequence motif 
remains with the rest of the enzyme. This is unique 
among the known activation mechanisms of different 
Members of the matrix metalloproteinase family (Fig. 
5). Fibroblast collagenase and stromelysin were auto- 
proteolytically processed by a two-step mechanism 
[6,7,9]. The M, 72,000 gelatinase followed a single-step 
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Fig. 5. Cleavages observed during activation of various mctal- 
!oproteinases induced by mercurial compounds. (a) PMNL type IV 
collapenase; (b) k4, 72000 type IV collagenase [5]; (c) PMNL col- 
lagenase 1191; (d) fibroblast collagenase [6]; (c) Abroblast collngenase 
[7]; (r) slromelysin [9]. 
activation mechanism but Okada et al. [S] discuss the 
intramolecular generation of an intermediate, so the 
activation is also thought to be a two-step process. 
Bllser et al. [19] found a three-step ropeptide trunca- 
tion for PMNL collagenase. These individual cleavage 
steps during the activation process refer on!y to the 
cleavages in the propeptide domain. 
C-Terminal truncation of a metalloproteinase during 
activation is presumed to ocour by He et al. [S] for the 
activation of collagenase by stromelysin. On the other 
hand, it could be shown that stromelysin exists in two 
active forms which share the same N-terminus. The M, 
45,000 form is only N-terminally truncated, whereas the 
rW, 28,000 active stromelysin has, in addition, lost the 
hemopexin-like domain [20]. 
Since cDNA sequences ofall metalloproteinases have 
become available, the differences in the domain struc- 
ture of these enzymes are obvious [21]. The smallest 
metalloproteinase, PUMP, consists of only two 
domains, the propeptide and the catalytic domain. In 
addition to this, all other metalloprotcinases have a 
hcmopexin-like, C-terminal region. Both type IV co]- 
lagenases (gelatinases) possess an insertion in the cata- 
lytic domain upstream of the zinc binding motif. This 
fibronectin-like insertion is responsible for the gelatin 
binding 121. Moreover, the Iw, 98,000 type IV col- 
lagenase contains a type V collagen like sequence, which 
is inserted before the prolin-rich region. Another im- 
portant difference between PMNL type IV collagenase 
and the other members of the matrix metalloproteinase 
family is the additional cysteine residue in the hemo- 
pexin-like domain. 
We could show that under non-reducing conditions, 
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protein fragments are generated and separated, proving 
that all three cysteine residues are not disulfide bridged. 
Such a high amount of free cytseine r sidues are uncom- 
mon. If the cysteine of the PRCGVPD region of type 
IV collagenase is assumed to be unbridged, it might 
interact with other disulfide bridges of the enzyme in an 
intramolecular disulfidc exchange reaction. This intm- 
molecular interchange might generate the free cysteines 
found in the isolated peptides. However, the higher mo- 
lecular rr?ass forms of type IV collagenase, which are 
formed from the M, 98,000 basic subunit of gelatinase 
with another M, 98,000 unit or the unidentified M, 
28,000 protein seems to indicate one or more disulfide- 
bridges between these molecules. This seems to support 
the assumption that type IV collagenase possesses more 
than just one free cysteine. 
Some site-directed mutagenesis experiments have 
confirmed the cysteine switch mechanism for transin 
[12,13]. The activation mechanism of type IV col- 
lagenase might be homologous to those of the other 
metalloproteinases. The four-step propeptide trunca- 
tion without the loss of the PRCGVPD region causes 
a conformational rearrangement around the Zn centre 
resulting in an active enzyme. The C-terminal split 
products found correspond to the ioss of the C-terminal 
domain of stromelysin and, therefore, have no effect on 
the activity of this enzyme. There are also special struc- 
tural features of the type IV collagenase, a unique 
member of the metalloproteinases with a type V col- 
lagen homologous domain and an additional cysteine 
residue in the hemopexin-like domain. This, taken to- 
gether with our findings of a relatively early loss of the 
Q&*6 but no loss of the Cys’” from the PRCGVPD 
sequence motif, seems to indicate a mechanism of 
activation by intramolecular cystcineldisulfide 
rearrangement tha t is different from the cysteine-switch 
mechanism [lO,ll], but identical in the result by gen- 
erating an accessible, catalytically active zinc at the en- 
zyme’s reactive site. 
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